Felzartamab, an investigational anti-CD38 monoclonal antibody, is a potentially differentiated therapeutic candidate with promise for a broad range of immune-mediated diseases ...
-- RBT-101, Radiant's lead oncology program and 4-1BB agonist, demonstrated robust, durable and complete tumor regression without liver toxicity in MC38 colorectal mouse tumor model -- Poster ...
Our latest Focus Issue looks at what we’ve learnt over the past decade and what’s next for the field of trained immunity.
HCB301 is a first-in-class tri-specific immunotherapy targeting SIRPα-CD47, PD-1/PD-L1, and TGFβ; it shows potent macrophage ...
London, 5 November 2025– LIfT BioSciences, (‘LIfT’ or ‘the Company’), a rapidly emerging biotech and the global leader in ...
Recently, a team led by Academician Hongjie Zhang, Researcher Shuyan Song, Associate Researcher Pengpeng Lei, and Dr. Ran An at the Changchun ...
Recently, a team led by Academician Hongjie Zhang, Researcher Shuyan Song, Associate Researcher Pengpeng Lei, and Dr. Ran An ...
When pathogens enter our cells as part of an infection, our body will trigger a programmed cell death known as "pyroptosis" ...
The global population is ageing and this demographic shift has profound effects on haemostasis, notably a progressive tilt ...
Recently, a team led by Academician Hongjie Zhang, Researcher Shuyan Song, Associate Researcher Pengpeng Lei, and Dr. Ran An at the Changchun Institute of Applied Chemistry, Chinese Academy of ...
Pancreatic cancer is notoriously hard to treat and often resists the most advanced immunotherapies. Northwestern Medicine ...
CoV-2, has led to the first approval of mRNA vaccines in humans. By producing the full-length SARS-CoV-2 Spike protein, they ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback